Detrimental effects of verapamil in patients with primary pulmonary hypertension.
Open Access
- 1 July 1984
- Vol. 52 (1) , 106-111
- https://doi.org/10.1136/hrt.52.1.106
Abstract
Calcium channel blockade provides a logical approach to the treatment of pulmonary hypertension because these drugs exert direct vasodilator effects in the highly constricted pulmonary circulation. To determine the effectiveness of verapamil in the treatment of primary pulmonary hypertension the haemodynamic effects of the drug were evaluated in seven patients with this disorder; 10 mg was given intravenously to six patients and 120 mg orally to one patient. Verapamil produced a 20% decline in pulmonary vascular resistance and a 27% decrease in mean pulmonary arterial pressure without significant changes in systemic vascular resistance. One patient who received verapamil 480 mg orally daily for three months showed sustained haemodynamic and clinical improvement. Concomitant with its beneficial effects on the pulmonary circulation, however, verapamil produced a pronounced decrease in right ventricular stroke work index (42%) and increase in right ventricular filling pressure (50%), indicating a direct depressant effect of the drug on right ventricular function. In one patient these cardiodepressant effects were sufficiently pronounced to produce severe hypotension and cardiac arrest. In conclusion, although verapamil appears to exert preferential vasodilator effects on the pulmonary circulation, its negative inotropic effects may be particularly detrimental to patients with primary pulmonary hypertension who have pre-existing right ventricular dysfunction; hence, treatment with verapamil is not recommended in such cases.This publication has 33 references indexed in Scilit:
- Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's PhenomenonNew England Journal of Medicine, 1983
- Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid HemorrhageNew England Journal of Medicine, 1983
- Deleterious Effects of Hydralazine in Patients with Pulmonary HypertensionNew England Journal of Medicine, 1982
- Regression of atherosclerosis in humans: fact or myth?Circulation, 1981
- Inhibition of Hypoxic Pulmonary Vasoconstriction by NifedipineNew England Journal of Medicine, 1981
- A Controlled Trial of Verapamil for Prinzmetal's Variant AnginaNew England Journal of Medicine, 1981
- Nifedipine Therapy for Coronary-Artery SpasmNew England Journal of Medicine, 1980
- Diazoxide in Primary Pulmonary HypertensionNew England Journal of Medicine, 1980
- Oral Hydralazine Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1980
- Primary Pulmonary HypertensionCirculation, 1970